Risks and Management Strategies for Kidney Transplantation with Extensive HLA Mismatches

Impact of HLA Mismatches on Transplant Outcomes

Extensive HLA mismatches in kidney transplantation significantly increase the risk of graft rejection, graft loss, and mortality, with each mismatch potentially reducing survival by 5-10% depending on disease risk status 1, 2
Mismatches at HLA-A, -B, -C, and -DRB1 are most critical and directly associated with increased mortality risk 2, 3
Each additional mismatch at these loci increases mortality risk in a dose-dependent manner, with greater impact (10% lower survival per mismatch) in low-risk disease patients compared to high-risk disease patients (5% lower survival per mismatch) 1, 3
HLA-DQ mismatches are increasingly recognized as critical risk factors for rejection and graft loss 4
54-77% of patients with de novo donor-specific antibodies (DSA) develop antibodies against HLA-DQ, which are associated with antibody-mediated rejection (ABMR), transplant glomerulopathy, and graft loss 4

The American Society of Transplantation recommends performing high-resolution DNA typing for all HLA loci to fully characterize potential allele-level mismatches 5
The American Journal of Transplantation suggests assessing for pre-existing donor-specific antibodies, especially in patients with prior sensitizing events (pregnancies, blood transfusions, previous transplants) 6
Implementing intensified induction immunosuppression due to the high number of mismatches is recommended by Kidney International 4
Maintaining higher target levels of maintenance immunosuppression, especially in the early post-transplant period, is suggested by Kidney International 4
The American Journal of Transplantation recommends implementing rigorous DSA monitoring schedule: weekly for the first month, then monthly for 6 months, then quarterly thereafter 6
Performing protocol biopsies to detect subclinical rejection, especially in the first year post-transplant, is recommended by the American Journal of Transplantation 6
Patients with multiple HLA-DQ mismatches who experience graft failure may become highly sensitized, making re-transplantation more difficult, according to Kidney International 4

Over half of long-term kidney graft failure can be attributed to DSA-mediated rejection, and approximately 30% of nonsensitized kidney transplant recipients develop de novo DSA within 10 years, with about 40% of patients losing their grafts within 5 years of DSA development, according to the Kidney International guidelines 7, 8, 9
Patients with intermediate- and high-risk profiles with mean tacrolimus levels <6 ng/ml versus >8 ng/ml have increased risk of DR/DQ de novo DSA development at 1 year, as recommended by the American Journal of Transplantation 10
The National Kidney Foundation suggests that a major concern with this degree of HLA-DQ mismatching is that if graft failure occurs, the recipient will likely become highly sensitized (>50% cPRA), making retransplantation extremely difficult, with a high risk of graft loss and mortality 7, 8, 9

The American Society of Transplantation recommends performing cross-matching to ensure no preformed DSA against this specific donor, to minimize the risk of antibody-mediated rejection 11
The American Journal of Transplantation suggests that patients with high eplet mismatch burden should undergo enhanced induction immunosuppression, with lymphocyte-depleting induction therapy and higher target levels of maintenance immunosuppression, especially during the first year post-transplant 10